Home
/ Greenwich Biosciences

Greenwich Biosciences

Greenwich Biosciences

Greenwich Biosciences Summary

Company Summary

Overview: Greenwich Biosciences is a biopharmaceutical company that develops cannabinoid prescription medicines. It offers EPIDIOLEX (cannabidiol), a prescription formulation of highly purified, plant-derived cannabidiol (CBD).

Type: Subsidiary

Status: Active

Founded: 2013

HQ: Carlsbad, CA, US | view all locations

Website: https://www.greenwichbiosciences.com/

Cybersecurity rating

Sectors

Table of Contents

Key People
Locations
Competitors
News

Key People

Justin Gover, Chief Executive Officer
Darren Cline, Chief Commercial Officer
Scott Giacobello, Chief Financial Officer
Volker Knappertz, Chief Medical Officer

and 1 others

LocationsView all

1 location detected

Carlsbad, CA HQ
United States
5750 Fleet St #200

Competitors and Similar Companies

Compare competitors

News

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting

Apr 13, 2021

Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Dec 1, 2020

Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

Nov 13, 2020

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

Oct 21, 2020

Footer menu

Product

Solutions

Resources

Company

© Craft.co 2023

Share price data provided by IEX